Psychoneuroendocrinology · 1996
Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment?
Клинический случайКлиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thibaut F, Cordier B, Kuhn J M
Аннотация
Six patients with severe paraphilia were treated with a long-acting gonadotrophin hormone releasing hormone analogue (GnRH-a). In five cases, the antiandrogen treatment ended their deviant sexual behaviour and markedly decreased their sexual fantasies and activities without significant side-effects. The beneficial effects of this treatment were maintained for 7 years in the patient where there was the longest follow-up. Two patients abruptly withdrew front their antiandrogen treatment at the end of the first and third year, respectively. Both relapsed within 8-10 weeks. One of them asked for resumption of antiandrogen treatment. In another case, in order to phase out antiandrogen treatment, testosterone (T) was added to the GnRH-a. In spite of normal T levels, and of resumption of normal sexual activities and deviant fantasies, deviant sexual behaviour did not return. A smoother phasing out of GnRH-a treatment is thought to be better than an abrupt withdrawal. However, the duration of antiandrogen treatment necessary to ensure a complete disappearance of deviant sexual behaviour remains uncertain, but is at least 4 years.
Предметные рубрики MeSH
AdolescentAdultBipolar DisorderBorderline Personality DisorderDelayed-Action PreparationsExhibitionismGonadotropin-Releasing HormoneHumansIntellectual DisabilityMaleMasturbationParaphilic DisordersPedophiliaPersonality DisordersPsychiatric Status Rating ScalesRecurrenceSubstance Withdrawal SyndromeTestosterone